NCT05020678 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05020678
Title	NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
Recruitment	Active, not recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Nkarta Inc.
Indications	B-cell acute lymphoblastic leukemia non-Hodgkin lymphoma mantle cell lymphoma lymphoma diffuse large B-cell lymphoma lymphoplasmacytic lymphoma chronic lymphocytic leukemia/small lymphocytic lymphoma
Therapies	Cyclophosphamide + Fludarabine NKX019
Age Groups:	adult \| senior
Covered Countries	USA \| AUS

NCT05020678
Clinical Trial Detail